Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
Status:
Recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded
to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with
a single oral dose of psilocybin. Followup visits to monitor safety and clinical outcome will
be conducted over a 3 month period.
Phase:
Phase 2
Details
Lead Sponsor:
New York State Psychiatric Institute
Collaborators:
COMPASS Pathways University of California, Los Angeles